Network-based elucidation of colon cancer drug resistance by phosphoproteomic time-series analysis
Rosenberger, G.; Li, W.; Turunen, M.; He, J.; Subramaniam, P. S.; Pampou, S.; Griffin, A. T.; Karan, C.; Kerwin, P.; Murray, D.; Honig, B.; Liu, Y.; Califano, A.
Show abstract
Aberrant signaling pathway activity is a hallmark of tumorigenesis and progression, which has guided targeted inhibitor design for over 30 years. Yet, adaptive resistance mechanisms, induced by rapid, context-specific signaling network rewiring, continue to challenge therapeutic efficacy. By leveraging progress in proteomic technologies and network-based methodologies, over the past decade, we developed VESPA--an algorithm designed to elucidate mechanisms of cell response and adaptation to drug perturbations--and used it to analyze 7-point phosphoproteomic time series from colorectal cancer cells treated with clinically-relevant inhibitors and control media. Interrogation of tumor-specific enzyme/substrate interactions accurately inferred kinase and phosphatase activity, based on their inferred substrate phosphorylation state, effectively accounting for signal cross-talk and sparse phosphoproteome coverage. The analysis elucidated time-dependent signaling pathway response to each drug perturbation and, more importantly, cell adaptive response and rewiring that was experimentally confirmed by CRISPRko assays, suggesting broad applicability to cancer and other diseases.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses 94%
- Pan-Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival 94%
- Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response 93%
Similar papers in this journal
Similar papers in this journal
- Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer 96%
- Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance 94%
- Impact of between-tissue differences on pan-cancer predictions of drug sensitivity 94%
Similar papers in this journal
- Illuminating oncogenic KRAS signaling by multi-dimensional chemical proteomics 96%
- Reporter-based screening identifies RAS-RAF stabilizing mutations as drivers of resistance to broad-spectrum RAS inhibition in colorectal cancer 93%
- Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.